Copyright: ©Author(s) 2026.
World J Nephrol. Mar 25, 2026; 15(1): 117173
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.117173
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.117173
Figure 1 Baseline vs follow-up urinary albumin-to-creatinine ratio values for 33 patients following finerenone therapy.
UACR: Urinary albumin-to-creatinine ratio.
Figure 2 Comparison of baseline and follow-up values for urinary albumin-to-creatinine ratio.
UACR: Urinary albumin-to-creatinine ratio.
Figure 3 Distribution of urinary albumin-to-creatinine ratio changes in responders vs non-responders after 24 weeks of finerenone treatment.
UACR: Urinary albumin-to-creatinine ratio.
Figure 4 Mean percentage change in urinary albumin-to-creatinine ratio by baseline urinary albumin-to-creatinine ratio group (all patients).
UACR: Urinary albumin-to-creatinine ratio.
Figure 5 Mean percentage change in urinary albumin-to-creatinine ratio by baseline urinary albumin-to-creatinine ratio group among responders.
UACR: Urinary albumin-to-creatinine ratio.
Figure 6
Comparison of baseline and follow-up values for serum potassium.
Figure 7
Distribution of adverse events during 24-week finerenone treatment period.
- Citation: Pasari AS, Gupta S, Gurjar P, Ramteke V, Malde S, Pawar T, Jeyachandran V, Kashiv P, Dubey S, Kurundwadkar M, Sejpal K, Bawankule C, Deshpande N, Balwani MR. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan. World J Nephrol 2026; 15(1): 117173
- URL: https://www.wjgnet.com/2220-6124/full/v15/i1/117173.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i1.117173